Tofersen, as an example, is an FDA-approved treatment for ALS cases associated with SOD1 mutations; this ASO was indeed designed to target SOD1 mRNA, limiting the expression of the mutant protein without affecting the host DNA [353]. The gene discussed is SOD1; the disease is amyotrophic lateral sclerosis.